Exclusive Summary

• Neostigmine Methylsulfate Injection is listed on the WHO Essential Medicines List, ensuring stable global clinical demand across anesthesia, ICU, and neurology departments.
• All patents have long expired with no IP barriers, allowing Chinese manufacturers to offer highly competitive generic pricing with full market access.
• The 2ml:1mg concentration aligns with international clinical practice for neuromuscular blockade reversal, making it straightforward to register and distribute in most markets.
• Emerging markets (Southeast Asia, Africa, Middle East, Latin America) show strong and growing demand with limited local manufacturing capacity, creating ideal conditions for distribution partnerships.
• Leading Chinese GMP-certified manufacturers can support regulatory compliance requirements across multiple markets, including WHO PQ-recognized facilities capable of supplying government and institutional procurement channels.